Eli Lilly, a leading U.S. pharmaceutical company, has entered into a $2.75 billion agreement with Hong Kong-based Insilico Medicine to bring AI-developed drugs to the global market [1]. The deal includes an upfront payment of $115 million to Insilico, with the remaining funds contingent upon regulatory and commercial milestones, as well as royalties on future sales [1]. Insilico Medicine has leveraged generative AI tools to develop at least 28 drugs, nearly half of which are already at the clinical stage, according to its founder and CEO, Alex Zhavoronkov [1]. Insilico went public in Hong Kong in December, and its shares have surged more than 50% year-to-date [1].
As part of the agreement, Insilico will join Lilly's Gateway Labs community for biotech development, further strengthening their collaboration, which began with an AI-based software licensing deal in 2023 [1]. Andrew Adams, group vice president of Molecule Discovery at Lilly, stated that the partnership will enable exploration of novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas, describing Insilico's AI-enabled discovery as a "powerful complement" to Lilly's clinical development [1].
Eli Lilly CEO David A. Ricks recently attended a high-level forum in Beijing, following the company's announcement of plans to invest $3 billion in China over the next decade. Last year, slightly less than 3% of Lilly's revenue was generated from China [1]. Insilico develops its AI outside of China, in Canada and the Middle East, but conducts early preclinical drug development in China based on its AI research [1]. Zhavoronkov highlighted that AI can reduce research time and synthesize molecules more quickly than traditional methods [1].
CONCLUSION
Eli Lilly's substantial $2.75 billion deal with Insilico Medicine marks a significant step in leveraging AI for drug development, with both companies poised to accelerate therapeutic innovation. The partnership is expected to have a high market impact, given Insilico's rapid progress and Lilly's global reach. Investors have responded positively, as evidenced by Insilico's share price surge, signaling optimism about the future of AI-driven pharmaceuticals.